Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: P ost‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin

• Published in: Diabetes, obesity & metabolism Vol. 20; no. 6; pp. 1542 - 1546
• Main Authors: Del Prato, Stefano, Rosenstock, Julio, Garcia‐Sanchez, Ricardo, Iqbal, Nayyar, Hansen, Lars, Johnsson, Eva, Chen, Hungta, Mathieu, Chantal
• Format: Journal Article
• Language: English
• Published: 01-06-2018
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.13258

The safety of triple oral therapy with dapagliflozin plus saxagliptin plus metformin versus dual therapy with dapagliflozin or saxagliptin plus metformin was compared in a
post‐hoc
analysis of 3 randomized trials of sequential or concomitant add‐on of dapagliflozin and saxagliptin to metformin. In the concomitant add‐on trial, patients with type 2 diabetes on stable metformin received dapagliflozin 10 mg/d plus saxagliptin 5 mg/d. In sequential add‐on trials, patients on metformin plus either saxagliptin 5 mg/d or dapagliflozin 10 mg/d received dapagliflozin 10 mg/d or saxagliptin 5 mg/d, respectively, as add‐on therapy. After 24 weeks, incidences of adverse events and serious adverse events were similar between triple and dual therapy and between concomitant and sequential add‐on regimens. Urinary tract infections were more common with sequential than with concomitant add‐on therapy; genital infections were reported only with sequential add‐on of dapagliflozin to saxagliptin plus metformin. Hypoglycaemia incidence was <2.0% across all analysis groups. In conclusion, the safety and tolerability of triple therapy with dapagliflozin, saxagliptin and metformin, as either concomitant or sequential add‐on, were similar to dual therapy with either agent added to metformin.